Researchers develop new COVID-19 vaccine AAVCOVID

May 22, 2020/prnewswire
BIOON /--Massachusetts Eye and Ear Hospital and Massachusetts General Hospital (MGH) recently announced the testing and development of an experimental vaccine, AAVCOVID, a new gene-based candidate vaccine for the fight against SARS-CoV2 virus that causes COVID-19AAVCOVID vaccine program was developed in the lab of DrLuk HVandenberghe, director of the GrousbeckCenter for Gene Therapyat the Massachusetts Eye and Ear Hospital and an associate professor of ophthalmology at Harvard Medical SchoolThe vaccine is currently in the preclinical development phase and is scheduled to begin clinical trials in humans later this yearDrMason Freeman, MGH Center for Translational Research and Founder, is leading clinical studies aimed at determining the safety and efficacy of experimental vaccinesAAVCOVID vaccine program is a unique, gene-based vaccine strategy that uses adeno-associated viruses (adeno-associated viral, AAV)vector, a clinically established gene transfer technique that uses thecharacteristics of harmless viralvectorsAAVs are used to transmit the genetic sequence of SARS-CoV-2 protrusion antigens so that the body can react to coronaviruses AAV technology has been widely used in the field of gene therapy , AAV-based drug production and clinical application has a wealth of experience and ability In recent years, the U.S Food and Drug Administration has approved two AAV-based drugs image source: https://cn.bing.com
AAVCOVID candidate vaccine will be given through intramuscular injection At present, animal model testing is under way, the initial production activities have begun Based on preclinical findings, one or more candidates will enter the clinical phase of the human test Although several new COVID-19 vaccines are being developed around the world, AAV technology has some unique advantages, including its adaptability and potential to induce a beneficial immune response to the human body In addition, other versions of AAV technology have been in clinical trials for more than 20 years have a good safety record "AAV is a costly technology for safe and efficient gene transfer, and the unique technical support we apply in AAVCOVID can induce strong immunity to SARS-CoV-2 with a single injection," says Dr Vandenberghe "In a crisis, we can use the power of molecular biology to develop a vaccine in a matter of weeks, and that's what we're doing here Clinical studies are now needed to determine the safety and effectiveness of our new approach Dr Freeman said: "While many organizations are working on a candidate vaccine for COVID-19 disease, it is far from certain what the best approach is Dr Vandenberghe's unique vaccine approach brings an elegant, innovative and creative approach to achieving our goals: protecting our most vulnerable patients and the health care providers who care for them during current and future virus outbreaks "
the team is recommended by experts from the Brigham Innovation Fund at Massachusetts General Hospital and Massachusetts General Hospital, and includes in-depth participation from industry experts with experience in vaccine development, regulatory affairs and production The study was funded by a charity led by Wyc Grousbeck, owner and chief executive of the Boston Celtics "That's what innovation looks like," said Joan W Miller, director of ophthalmology at the Massachusetts Eye and Ear Hospital It was the scientific insight struck by Dr Vandenberghe and his team, along with the flexibility and collaborative spirit of a large number of institutions and donors, to move the project forward at a lightning speed from the idea of a vaccine candidate John Fernandez, president of the MIT, said: "We are deeply grateful to all those involved in this partnership, especially the generous donors who pioneered the initial funding for the project "The unprecedented coronavirus pandemic poses a challenge to all of us, overcoming the best thinking and most creative ideas of our scientific and clinical teams, supported and strengthened by our charitable organization," said Peter L Slavin, MGH,m., MGH President "This spirit of innovation, determination and generosity is our most powerful weapon against this terrible virus "
on AAVCOVID technology
AAVCOVID vaccine program is a gene-based vaccine strategy designed to transmit SARS-CoV-2 gene sequences using adeno-related virus vector (AAV), a harmless virus that can enter the human body as a delivery vector vaccinated with AAVCOVID, providing the gene code for antigens after intramuscular injections of low-dose SARS-CoV-2 protoscent proteins, with the aim of triggering an immune response to prevent infection This approach is supported by other diseases, including the safety of using AAVs in two drugs approved by the FDA , preclinical research data for immunogenicity, and extensive experience with the AAV technology platform after the genetic sequence of the new coronavirus was first announced, Dr Vandenberghe and his lab began research on the vaccine By using specific AAVs with ideal vaccine characteristics, the program seeks to induce immunity in healthy populations to prevent infection and disease AAV is also a fast-adapted technology If a new STRAIN of SARS-CoV-2 is present, the genetic in the AAVCOVID vaccine can be updated and processed into an updated vaccine within weeks, the researchers said (BioValleyBioon.com) References: 1
Researchers- "Researchers" of the novel trial iced-based COVID-19 vaccine, AAVCOVIDVID
2) -Clinical clinically clinically-in-the-
-19-
3